ストックスクリーナーアプリを入手
8.425
0.96%
0.075
前日終値:
$8.35
開ける：
$8.38
24時間の取引高:
345.54K
Relative Volume:
0.08
時価総額：
$1.76B
収益：
$503.49M
当期純損益:
$-53.47M
株価収益率:
-32.40
EPS:
-0.26
ネットキャッシュフロー:
$-26.89M
1週間 パフォーマンス:
+6.04%
1か月 パフォーマンス:
-4.10%
6か月 パフォーマンス:
-3.33%
1年 パフォーマンス:
+5.77%
1日の値動き範囲:
$8.30
$8.45
1週間の範囲:
$8.095
$9.14
52週間の値動き範囲:
$6.015
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
名前
Biocryst Pharmaceuticals Inc
セクター
電話
919-859-1302
住所
4505 EMPEROR BOULEVARD, DURHAM, NC
BCRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.42 | 1.81B | 503.49M | -53.47M | -26.89M | -0.26 |
|
ZTS
Zoetis Inc
|
146.69 | 64.93B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.43 | 45.07B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.49 | 41.53B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.16 | 18.37B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
302.22 | 13.68B | 2.99B | 1.21B | 1.13B | 25.06 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-02-25 | 開始されました | Wedbush | Outperform |
| 2023-11-20 | 再開されました | JP Morgan | Overweight |
| 2023-09-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-13 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-02-22 | アップグレード | Needham | Hold → Buy |
| 2022-11-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2022-08-05 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-05 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-04-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-04-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-12-10 | 開始されました | Oppenheimer | Outperform |
| 2021-08-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-03 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-03-01 | 開始されました | Cowen | Outperform |
| 2020-09-29 | 再開されました | JP Morgan | Overweight |
| 2020-06-17 | 開始されました | BTIG Research | Neutral |
| 2020-05-05 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-11-15 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | 再開されました | Piper Jaffray | Overweight |
| 2018-08-08 | 再開されました | JP Morgan | Overweight |
| 2018-07-17 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | 開始されました | Seaport Global Securities | Neutral |
| 2018-01-02 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | 開始されました | Barclays | Equal Weight |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-09-06 | アップグレード | Jefferies | Hold → Buy |
| 2017-02-16 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-08-12 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 繰り返されました | FBR Capital | Outperform |
| 2016-02-09 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2016-02-09 | ダウングレード | Needham | Buy → Hold |
すべてを表示
Biocryst Pharmaceuticals Inc (BCRX) 最新ニュース
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
BioCryst Pharmaceuticals 2025 Q2 Earnings Record Net Income Surges 140% - AInvest
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Awards Massive Stock Package: 10 New Hires Get 126,450 Shares in Options and RSUs - Stock Titan
BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves - TipRanks
BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances - MSN
BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating - TipRanks
BioCryst (BCRX) Q2 Revenue Jumps 50% - AOL.com
BioCryst Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
BioCryst: Q2 Earnings Snapshot - New Haven Register
BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... - Yahoo Finance
BioCryst Pharmaceuticals Reports Record Q2 2025 Results - TipRanks
BioCryst Pharmaceuticals: A Strategic Blueprint for $1 Billion in ORLADEYO Revenue by 2027 - AInvest
BioCryst Pharmaceuticals' Q2 2025: Unpacking Contradictions in ORLADEYO Demand, Market Share, and Financial Metrics - AInvest
BioCryst Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level - Stocktwits
BioCryst Pharmaceuticals Soars 15.35% on Strong Earnings - AInvest
Earnings call transcript: BioCryst Q2 2025 sees strong earnings beat, shares surge - Investing.com
BioCryst Pharmaceuticals Reports Impressive Q2 EarningsNews and Statistics - IndexBox
BioCryst Keeps Momentum With Strong ORLADEYO Sales And Rising Profits - Finimize
BioCryst Pharma soars 6.4% as Q2 results crush expectations - Investing.com
BioCryst Q2 2025 slides: ORLADEYO demand surges, profitability accelerates By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
BioCryst Pharmaceuticals: A High-Conviction Biotech Play with a Defensible Moat in Rare Disease Innovation - AInvest
BioCryst Reports Strong Q2 2025 Financial Performance - TipRanks
Is This the Dip to Buy in BioCryst Pharmaceuticals Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
BioCryst (BCRX) Q2 Revenue Jumps 50% - The Motley Fool
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Is it the right time to buy BioCryst Pharmaceuticals Inc. stockTrack high-yield stocks before they peak - Jammu Links News
What is the dividend policy of BioCryst Pharmaceuticals Inc. stockDiscover undervalued stocks before they soar - Jammu Links News
BioCryst Pharmaceuticals Inc. Stock Analysis and ForecastTrack top-performing stocks effortlessly - Jammu Links News
How strong is BioCryst Pharmaceuticals Inc. company’s balance sheetCapitalize on emerging industry trends - Jammu Links News
What makes BioCryst Pharmaceuticals Inc. stock price move sharplyMaximize gains with expert analysis - Jammu Links News
How does BioCryst Pharmaceuticals Inc. compare to its industry peersDiscover breakthrough stocks before the crowd - Jammu Links News
Is BioCryst Pharmaceuticals Inc. a growth stock or a value stockInvest confidently with professional market insights - Jammu Links News
When is BioCryst Pharmaceuticals Inc. stock expected to show significant growthStrong return on investment - Jammu Links News
How volatile is BioCryst Pharmaceuticals Inc. stock compared to the marketBuild wealth steadily with smart stock selection - Jammu Links News
What catalysts could drive BioCryst Pharmaceuticals Inc. stock higher in 2025Unlock expert stock analysis and alerts - Jammu Links News
What are the technical indicators suggesting about BioCryst Pharmaceuticals Inc.Double or triple returns - Jammu Links News
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO - MSN
Is BioCryst Pharmaceuticals Inc. a good long term investmentFree Stock Market Query - Jammu Links News
Is BioCryst Pharmaceuticals Inc. stock overvalued or undervaluedFind the best stocks for sustainable growth - Jammu Links News
BioCryst Pharmaceuticals Q2 2025 Earnings Preview: Revenue Expected to Rise 37% YoY - AInvest
BioCryst Announces New President Amid Leadership Change - The Globe and Mail
Healthcare Triangle, Inc. shares fall 3.23% after-hours as BioCryst Pharmaceuticals announces CEO transition. - AInvest
BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse - GlobeNewswire
BioCryst Pharmaceuticals' Leadership Transition: Strategic CEO Appointment and Its Impact on Pipeline Execution and Shareholder Value Creation - AInvest
BioCryst Pharmaceuticals Before Q2 Earnings: How To Play The Stock - Barchart.com
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock - The Globe and Mail
Biocryst Pharmaceuticals Inc (BCRX) 財務データ
収益
当期純利益
現金流量
EPS
0.23%
1.12%
大文字化:
|
ボリューム (24 時間):